相控阵热疗联合吉西他滨治疗胰腺癌的临床观察

《相控阵热疗联合吉西他滨治疗胰腺癌的临床观察》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、相控阵热疗联合吉西他滨治疗胰腺癌的临床观察川北医学院第二临床学院肿瘤中心四川南充637000【摘要】目的：观察相控阵热疗联合吉西他滨治疗胰腺癌的疗效及毒性反应。方法：34例伴有疼痛的局部晚期和复发的胰腺癌患者随机分为热疗联合吉西他滨化疗组(研究组)17例和单纯吉西他滨化疗组(对照组)17例，研究组接受相控阵热疗，每周2次，计划8次，联合吉西他滨1000mg/m2,dl、8、15,每28天重复一次，对照组接受吉西他滨1000mg/m2,dl、8、15,每28天重复一次，观察阿片类药物剂量增减情况、毒副反应及近期疗效。结果：治疗开始2个月内，研究组阿片类药物用量减少大于对

2、照组(P<0.01),2组患者IIIJV度白细胞降低、血小板降低发生率无差异(P>0.05),近期有效率在研究组和对照组分别为20.2%(3/15)和13.3%(2/15),(P>0.05)。结论：相控阵热疗联合吉西他滨治疗局部晚期和复发胰腺癌，与单用吉西他滨相比，能明显减少阿片类药物用量，毒性反应轻，近期疗效无差异。【关键词】胰腺癌；相控阵热疗；吉西他滨【中图分类号】R735.9【文献标识码】B【文章编号】1764-8999(2015)7-0749-02Clinicalobservationofarraysystenforhyperthermiacombinedwi

3、thgemcitabineforpancreaticcarcinomaHUXin,LIGuang-ming,WENShi-min,LIShuang,CHENSi-lin,PANRong-qiang,BIEJun,ZHAOCai-xia,FUXi,CHENQiao-ling,SONGJun-mei,HUXing-sheng,(DepartmentofOncology,SecondClinicalInstituteofNorthSichuanMedicalCollege,NanchongSichuan637000China)【Abstract】Objective:Toob

4、servetheefficacyandtoxicityofarraysystemforhyperthermiagemcitabineforpancreaticcarcinoma.Methods:34casespatientswithlocaladvancedandrecurrentpancreaticcarcinomawererandomlybydividedintostudygroup17casestreatedwitharraysystemforhyperthermia2timesaweekcombinedwithgemcitabine(1000mg/m2dl,8

5、,15,per28dayacycle)andcontrolgrouptreatedwithalonegemcitabine(1000mg/m2£11,8,15,per28dayacycle),theincreaseanddecreaseofopioidconsumptionwererecordedandtoxicityandshort-timeeffectwereobserved.Results:Inthenext2monthsafterbeginningtherapy,theopioidconsumptionofstudygroupwasdecreasedmoret

6、hanthatofcontrol(P<0.01),therewerenotsignificantdifferencebetween2groupinIII-IV°leukocytopenia(P>0.05)andIII-IV°thrombocytopenia(P>0.05),theshort-timeresponseratewas20.0%(3/15)instudygroupand13.3%(2/15)incontrolgroup(P>0.05).Conclusion:Comparedwithalonegemcitabine,arraysystemfor

7、hyperthermiacombinedwithgemcitabineforlocaladvaneedandrecurrentpancreaticcarcinomacansign讦icantlydecreaseopioidconsumption.【KEYWORDS]Arraysystemforhyperthermia;Gemcitabine;Pancreaticcarcinoma.胰腺癌是恶性程度极高的消化道肿瘤，目前手术作为唯一根治手段，由于超过80%患者确诊吋已属晚期，可行根治性切除手术者不足20%,术后5年生存率低于4%,局部复发是主要的治疗失